These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 4147555)

  • 1. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.
    Gut; 1973 Aug; 14(8):637-41. PubMed ID: 18668841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
    Azad Khan AK; Nurazzaman M; Truelove SC
    J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different therapy for different types of ulcerative colitis in China.
    Jiang XL; Cui HF
    World J Gastroenterol; 2004 May; 10(10):1513-20. PubMed ID: 15133864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the colon in the metabolism of salicylazosulphapyridine.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
    [No Abstract]   [Full Text] [Related]  

  • 13. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
    Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
    Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.